Conditions: Coronary Artery Disease (CAD)
Keywords: CAD
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 15
Healthy volunteers: no

Brief summary:
There are two separate objectives in this study:

1. To demonstrate the pharmacodynamic (PD) profile when participants treated with cangrelor are switched to oral prasugrel 60 mg administered 30 minutes (min) after cangrelor infusion is discontinued
2. To demonstrate the PD profile when participants treated with cangrelor are switched to oral clopidogrel 600 mg administered during or immediately after cangrelor infusion.

Detailed description:

Arms:
arm 1: Prasugrel 60 milligram (mg) administered orally 30 min after the discontinuation of cangrelor infusion on Day 1 (2.5 hours \[hrs\] after initiation of cangrelor infusion). arm 2: Clopidogrel 600 mg administered orally within 5 min after the discontinuation of the cangrelor infusion on Day 1 (2 hrs after initiation of cangrelor infusion). arm 3: Clopidogrel 600 mg administered orally 1.5 hrs after the initiation of cangrelor infusion on Day 1. arm 4: Clopidogrel 600 mg administered orally 1 hr after the initiation of cangrelor infusion on Day 1.

Interventions: intervention 1: Cangrelor intervention 2: Clopidogrel intervention 3: Prasugrel
Intervention descriptions: intervention 1: Cangrelor intravenously (IV) administered as a 30 microgram (µg)/kilogram (kg) bolus, followed by 4 µg/kg/min infusion for 2 hrs on Day 1. intervention 2: Clopidogrel 600 mg single oral dose intervention 3: Prasugrel 60 mg single oral dose

Protocol document: